Skip to main content

Table 9 Multivariate Cox regression analyses of overall survival for four molecular subtypes of T1c breast cancer patients in the matched cohort

From: Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort

Variable

HoR + /HER2-

HoR + /HER2 + 

HoR-/HER2 + 

HoR-/HER2-

Multivariate Analysis

Multivariate Analysis

Multivariate Analysis

Multivariate Analysis

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

GRADE

 I

reference

 

reference

 

reference

 

reference

 

 II

1.27(0.92–1.77)

0.14

1.02(0.54–1.93)

0.95

0.19(0.04–0.88)

0.03

1.71(0.69–4.24)

0.25

 III

1.74(1.26–2.40)

 < 0.01

1.12(0.58–2.13)

0.74

0.19(0.04–0.83)

0.03

2.19(0.90–5.31)

0.08

SURGERY

 Breast-conserving

reference

 

reference

 

reference

 

reference

 

 Total mastectomy

0.54(0.40–0.74)

 < 0.0001

0.60(0.40–0.89)

0.01

0.41(0.21–0.78)

0.01

0.67(0.49–0.91)

0.01

 Modified radical mastectomy

0.75(0.52–1.09)

0.13

0.52(0.29–0.93)

0.03

0.53(0.23–1.21)

0.13

0.55(0.36–0.85)

0.01

RADIATION

 No

reference

 

reference

 

reference

 

reference

 

 Yes

0.36(0.26–0.48)

 < 0.0001

0.37(0.25–0.56)

 < 0.0001

0.36(0.16–0.77)

0.01

0.48(0.35–0.66)

 < 0.0001

CHEMOTHERAPY

 No

reference

 

reference

 

reference

 

reference

 

 Yes

0.61(0.51–0.74)

 < 0.0001

0.42(0.30–0.58)

 < 0.0001

0.33(0.19–0.59)

 < 0.0001

0.35(0.27–0.44)

 < 0.0001

AGE (year)

 < 60

reference

 

reference

 

reference

 

reference

 

 ≥ 60

3.62(2.98–4.41)

 < 0.0001

3.27(2.13–5.02)

 < 0.0001

2.59(1.34–5.04)

 < 0.01

2.01(1.50–2.69)

 < 0.0001

  1. Abbreviations: HoR hormone receptor, HER2 human epidermal growth factor receptor‐2, HR hazard ratio